Related Experiment Video
Updated: Jan 22, 2026

Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma
Published on: October 27, 2014
Phase II study of Dovitinib in recurrent glioblastoma
Mayur Sharma1, Cathy Schilero1, David M Peereboom1,2
1Burkhardt Brain Tumor and Neuro-Oncology Center, Neurological Institute, Cleveland Clinic, 9500 Euclid Ave, S73, Cleveland, OH, 44195, USA.
Introduction:
Dovitinib is an oral, potent inhibitor of FGFR and VEGFR, and can be a promising strategy in patients with recurrent or progressive glioblastoma (GBM).
Methods:
This was an open label phase II study of two arms: Arm 1 included anti-angiogenic naïve patients with recurrent GBM and Arm 2 included patients with recurrent GBM that had progressed on prior anti-angiogenic therapy. Nineteen subjects were enrolled in Arm 1 and 14 subjects in Arm 2. The primary endpoint was 6-month progression-free survival (PFS-6) in Arm 1 and time to progression (TTP) in Arm 2. The secondary endpoints were toxicity, objective response rate (ORR) and overall survival.
Results:
Patients in Arm 2 (compared to Arm 1) tended to have longer intervals from diagnosis to study entry (median 26.9 vs. 8.9 months, p = 0.002), experienced more recurrences (64%, had 3-4 prior recurrences compared to 0, p < 0.0001) and tended to be heavily pretreated (71% vs. 26-32% p = 0.04 or 0.02). 6-month PFS was 12% ± 6% for the Arm 1 and 0% for Arm 2. TTP was similar in both treatment arms (median 1.8 months Arm 1 and 0.7-1.8 months Arm 2, p = 0.36). Five patients (15%) had grade 4 toxicities and 22 patients (67%) had grade 3 toxicities. There were no significant differences between the two arms with respect to the amount of change in the levels of biomarkers from baseline.
Conclusion:
Dovitinib was not efficacious in prolonging the PFS in patients with recurrent GBM irrespective of prior treatment with anti-angiogenic therapy (including bevacizumab).
Insights
Dovitinib did not improve progression-free survival in recurrent glioblastoma (GBM) patients, regardless of prior anti-angiogenic therapy. The study found no significant efficacy in prolonging PFS for GBM patients treated with dovitinib.
Area of Science:
- Oncology
- Pharmacology
Background:
- Dovitinib is an oral inhibitor targeting FGFR and VEGFR.
- It was investigated as a potential treatment for recurrent or progressive glioblastoma (GBM).
Purpose of the Study:
- To evaluate the efficacy of dovitinib in patients with recurrent GBM.
- To compare outcomes in anti-angiogenic-naïve patients versus those with prior anti-angiogenic therapy.
Main Methods:
- An open-label, two-arm phase II study was conducted.
- Arm 1: anti-angiogenic-naïve recurrent GBM patients.
- Arm 2: recurrent GBM patients progressed on prior anti-angiogenic therapy.
Main Results:
- Six-month progression-free survival (PFS-6) was 12% in Arm 1 and 0% in Arm 2.
- Time to progression (TTP) was similar between arms (median 1.8 months vs. 0.7-1.8 months).
- High rates of grade 3 and 4 toxicities were observed (67% and 15%, respectively).
Conclusions:
- Dovitinib demonstrated no efficacy in prolonging PFS for recurrent GBM patients.
- Efficacy was not observed irrespective of prior anti-angiogenic treatment, including bevacizumab.
Related Concept Videos
Phase Diagrams
Phase Transitions
Inductance: Single-Phase And Three-Phase Line
Single-Phase Two-Wire Line:
A single-phase line consists of two solid cylindrical conductors, denoted as x and y. Each conductor carries phasor currents ix and iy, respectively. Given that the sum of these currents is...
Capacitance: Single-Phase And Three-Phase Line
Single-Phase Lines
Consider a single-phase, two-wire transmission line with equal phase spacing energized by a voltage source. One conductor carries a uniform positive charge, while the other carries an equal negative charge. The capacitance C of the line can be derived from the voltage V between the conductors. For a one-meter section of the line, the capacitance is given...
Phase Changes
A substance melts or freezes at a temperature called its melting point and boils or condenses at its boiling point. These temperatures depend on pressure. High pressure favors the denser form of the substance, so typically, high pressure...
Phase-lead and Phase-lag Controllers

